|1.||Peters, C: 2 articles (06/2014 - 07/2008)|
|2.||Vasiljeva, O: 2 articles (06/2014 - 07/2008)|
|3.||Krüger, A: 2 articles (06/2014 - 07/2008)|
|4.||Reinheckel, T: 2 articles (06/2014 - 07/2008)|
|5.||Turk, B: 2 articles (06/2014 - 07/2008)|
|6.||Mohr, Lena K M: 1 article (10/2015)|
|7.||Krohne, Tim U: 1 article (10/2015)|
|8.||Hoffmann, Andrea V: 1 article (10/2015)|
|9.||Brandstetter, Carolina: 1 article (10/2015)|
|10.||Holz, Frank G: 1 article (10/2015)|
06/26/2014 - "However, upon treatment with the lysosomotropic agent Leu-Leu-OMe, cancer cells lacking Stfb exhibited a significantly higher sensitivity to apoptosis. "
07/10/2008 - "However, cancer cells lacking Ctsb exhibited significantly higher resistance to apoptosis induction by the lysosomotropic agent Leu-Leu-OMe. "
02/15/1992 - "The myeloid tumor lines U937, HL60, and THP-1 were found to be uniformly enriched in DPPI and susceptible to Leu-Leu-OMe but not Leu-OMe toxicity. "
08/15/1986 - "Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets."
02/01/1986 - "It was found that a variety of tissue culture cells and tumor lines of nonlymphoid origin were completely resistant to any demonstrable Leu-Leu-OMe-mediated toxicity. "
|2.||Graft vs Host Disease (Graft-Versus-Host Disease)
01/01/1987 - "Lethal graft vs host disease (GVHD), which developed in irradiated (C57BL/6 X DBA/2)F1 recipients of C57BL/6 bone marrow and spleen cells was completely prevented by Leu-Leu-OMe treatment of donor cells. "
01/01/1987 - "Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells."
06/01/1992 - "Treatment of murine spleen cells (SpC) with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) depletes L3T4(+) and Lyt2(+) cytotoxic T lymphocyte precursors and the capacity to generate lethal graft-versus-host disease in semiallogeneic class I + II MHC and multiple non-MHC-disparate recipient mice, whereas T helper cell function is preserved. "
11/15/1988 - "Treatment of C57BL/6J (B6) murine splenocytes with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) selectively removes NK cells, CTL precursors, and the capacity to cause lethal graft-vs-host disease (GVHD) in irradiated B6 X DBA/2 F1 mice. "
10/01/1987 - "Thus, Leu-Leu-OMe treatment of B6 donor cells not only prevents lethal graft-vs-host disease, but also permits establishment of long-lived parent----F1 chimeras that are selectively tolerant of host H-2 disparate alloantigens, but fully immunocompetent with respect to natural killer cell function, B and T cell mitogenesis, and anti-third party alloresponsiveness."
|3.||Phototoxic Dermatitis (Phototoxicity)
03/15/2013 - "Strikingly, cathepsin C deficiency not only blocked Leu-Leu-OMe-mediated necrosis but also impaired Leu-Leu-OMe-enhanced immunity. "
03/15/2013 - "We identified cathepsin C as critical for Leu-Leu-OMe-induced cell death, whereas cathepsins B and S were required for alum-mediated necrosis. "
|5.||Melanoma (Melanoma, Malignant)
08/01/1995 - "Pathogenic Acanthamoeba trophozoites were incubated with human ocular melanoma (OCM1) cells for 30 min, 1 hr, and 3 hr. The amoebae were treated with a calcium ionophore (A23187), phorbol myristate ester (PMA), calcium channel blocker (Bepridil), cytochalasin D, and L-leucyl-L-leucine methyl ester (leu-leu-OMe). "
|3.||Myristic Acid (Tetradecanoic Acid)
|6.||Calcium Channels (Calcium Channel)